Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study
Authors' conclusion
Real-world semaglutide users generally resembled trial participants, but few follow the dose titration schemes tested in premarket clinical trials.
Study context
- Population
- Danish adults filling semaglutide (Wegovy) prescriptions, 12 December 2022 to 31 December 2023; median age 49 years, 70% female773,708 prescriptions
- Participants
- 110,748 adults
- Outcome
- Patient characteristics, prescriber type and dose titration patterns
Main finding
As reported in the abstract
Patient characteristics, prescriber type and dose titration
- Treatment initiated by general practitioners
- 86%
- Hypertension
- 30%
- Dyslipidemia
- 17%
- Arthrosis
- 17%
- Reached maximum dose 2.4 mg by fifth prescription
- 13%
- Stopped after first prescription
- 5.7%
- Followed recommended dose increases every 4 weeks
- 10%
- Filled ≥1 prescription of 2.4 mg
- 25%
- Continued 1.0-mg dosage from fourth prescription onward
- 33-48%
Observational data: associations, not effects.
Original publication
Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study. Diabetes Care. Published 6 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →